- Home
- NRXS vs JSPR Comparison
NRXS vs JSPR Comparison
Compare NRXS & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | JSPR |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 43.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRXS | JSPR |
|---|---|---|
| Price | $4.90 | $1.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $8.00 | ★ $18.13 |
| AVG Volume (30 Days) | 151.4K | ★ 939.0K |
| Earning Date | 11-10-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,362,320.00 | N/A |
| Revenue This Year | $31.05 | N/A |
| Revenue Next Year | $137.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.89 | N/A |
| 52 Week Low | $1.33 | $1.39 |
| 52 Week High | $6.20 | $7.19 |
Technical Indicators
Market Signals| Indicator | NRXS | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 64.62 | 42.27 |
| Support Level | $4.33 | $1.47 |
| Resistance Level | $5.05 | $1.63 |
| Average True Range (ATR) | 0.32 | 0.15 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 67.82 | 20.45 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.